Overview
Background
Andrew Martin is inaugural Professor of Innovative Clinical Trials and leads the University of Queensland’s cLinical Trials cApability (ULTRA) program. Andrew was Professor in the biostatistics group at the NHMRC Clinical Trials Centre University of Sydney. He maintains that role in an honorary capacity since joining UQ. Prior to academia, Andrew held senior biostatistics roles within research-based pharmaceutical organisations (Pfizer and Roche).
Grants
Category 1: $14.3M Category 3: $131.8M
Grants: 2023 Clinical Trials and Cohort Studies Grant ID 2032441 ($1,362,000): P3BEP Trial - Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours; 2022 NHMRC Partnership Projects Grant 2015773 ($1,166,592): Strengthening healthcare systems with Patient Reported Outcome Measures (PROMs); 2020 CA ($600,000): Immuno-metabolic biomarkers for metastatic prostate cancer treatment response; 2018 MRFF Grant APP1170066 ($1,596,631): WHEAT Study on reducing NEC in preterm infants; 2018 CA Grant APP1158397 ($479,375): SCORE trial for shared colorectal cancer care; 2018 CA Grant APP1159837 ($600,000): P3BEP Trial for advanced germ cell tumours; 2018 NHMRC Project Grant APP1159787 ($1,587,163): BCG+MM Trial for bladder cancer; 2016 Victorian Cancer ($300,000): SCORE project on shared care of Colorectal cancer survivors; 2015 CA Priority-driven Collaborative Cancer Research Scheme ($443,307): LEAD - Lung cancer diagnostic and treatment pathways; 2015 NHMRC Project Grant 1108328 ($624,824): Oral Nicotinamide for skin cancer chemoprevention after Transplant; 2014 Co-funded Grant 1079794 ($597,095): Methoxyflurane to reduce discomfort of prostate biopsy; 2013 NHMRC Project Grant 1064121 ($880,425): CHEST Australia project for quicker primary care consultations in lung cancer; 2012 NHMRC Project Grant APP1047100 ($2,203,171): Bovine lactoferrin study on low birthweight infants; 2011 National Breast Cancer Foundation ($199,606): Physical well-being for metastatic breast cancer; 2011 NHMRC Project Grant 1028555 ($187,018): Evidence on reduced child obesity rates; 2011 NHMRC Project Grant 1026977 ($586,691): Oral nicotinamide for skin cancer prevention; 2011 Australasian College of Dermatologists grant ($25,000): Nicotinamide for non-melanoma skin cancer in renal transplant recipients; 2010 NHMRC Project Grant 1007628 ($369,208): NEU-HORIZONS study on riluzole for oxaliplatin neurotoxicity; 2010 NHMRC Project Grant 1003414 ($564,410): Phase II prostate cancer follow-up trial in primary care.
Statistical lead on the following projects receiving industry funding with USyd as administering institution: ENZARAD NCT02446444 ($12,178,000); ENZAMET NCT02446405 ($20,408,129); INTEGRATE ACTRN12612000239864 ($6,900,000); INTEGRATE IIa ACTRN12616000420448 ($22,264,248); INTEGRATE IIb NCT04879368 ($36,330,215); DASL-HiCaP NCT04136353 ($33,777,579).
Availability
- Professor Andrew Martin is:
- Available for supervision
Research impacts
Research Achievements and Collaborations: Has made original, innovative, and distinguished contributions to methodological research, as well as the design, conduct, analysis, interpretation, and dissemination of clinical research that has had an impact at an international level policy, practice, and subsequent research programs. Has been responsible for the provision of statistical leadership to collaborative trials groups to design, undertake, analyse, and report on clinical trials, as well as promoting investigator-initiated research activities. 2020-2024 Scopus/SciVal author publication metrics: FWCI of 5.21, 51% in top 10% most cited worldwide, 39% international collaboration 3,763 citations (10,934 overall). Received the 2020 ACTA (Australian Clinical Trials Alliance) Statistics in Trials Interest Group Excellence in Trial Statistics Award for ENZAMET Trial. Research funding in last 5 years: $3.1M category 1 and $76.7M category 3.
Contributions to the Field: Led methodological research with international impact. Examples in the last 5 years focus on the topic of changes to the design of ongoing trials. This work has been cited in the CONSERVE 2021 Statement (JAMA. 2021;326(3):257-265 FWCI 7.38; top 1% of general medical journals). Also co-published innovative method for appropriately adjusting estimates of effect obtained from trials that terminate early based on the results of an interim analysis (Statistical Methods in Medical Research – top 11% for statistics journals). Co-designed andled the statistical aspects of design, conduct, analysis, and interpretation of many trial. Two key examples in the last 5 years include ENZAMET and TheraP. (1) ENZAMET study selected for plenary presentation at ASCO (peak international clinical oncology conference attended by over 30,000 international delegates). Am second author for both main N Engl J Med paper (2019;381:121) (journal ranked top 1% general medicine), the quality of life J Clin Oncol paper (2022;40:837-46) (journal ranked top 2% cancer research), and the follow-up Lancet Oncol paper (2022;23:1389) (journal ranked top 1% cancer research). Results were used in support of successful registration of enzalutamide with US FDA in this indication and have been incorporated into US and European treatment guidelines. (2) TheraP evaluated efficacy of cutting-edge targeted radiopharmaceutical (Lu-PSMA) in advance prostate cancer that delivers radiation to cells expressing the prostate-specific membrane antigen. Selected for oral presentation at highly prestigious ASCO 2020 and ASCO GU 2021 conferences. Second senior author of The Lancet paper (2021;397:797) (journal ranked top 1% general medicine). Has led to 2 additional RCTs of Lu-PSMA that I co-designed. One (ENZA-p) was just published in Lancet Oncol (2024 Apr 12:S1470-2045(24)00135-9) (journal ranked top 1% cancer research).
Works
Search Professor Andrew Martin’s works on UQ eSpace
2016
Journal Article
A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients
Chen, A. C., Martin, A. J., Dalziell, R. A., McKenzie, C. A., Lowe, P. M., Eris, J. M., Scolyer, R. A., Dhillon, H. M., Vardy, J. L., Bielski, V. A., Halliday, G. M. and Damian, D. L. (2016). A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. British Journal of Dermatology, 175 (5), 1073-1075. doi: 10.1111/bjd.14662
2015
Journal Article
BCG+MMC trial: Adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: A randomised phase III trial (ANZUP 1301)
Hayne, Dickon, Stockler, Martin, McCombie, Steve P., Chalasani, Venu, Long, Anne, Martin, Andrew, Sengupta, Shomik and Davis, Ian D. (2015). BCG+MMC trial: Adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: A randomised phase III trial (ANZUP 1301). BMC Cancer, 15 (1) 432. doi: 10.1186/s12885-015-1431-6
2015
Conference Publication
RANDOMISED PHASE 3 TRIAL OF THE ADDITION OF MITOMYCIN TO BCG AS ADJUVANT INTRAVESICAL THERAPY FOR HIGH-RISK, NON-MUSCLE-INVASIVE BLADDER CANCER(ANZUP 1301)
Chalasani, Venu, Sengupta, Shomik, Stockler, Martin, McCombie, Steve, Hawks, Cynthia, Krieger, Laurence, Anderson, Paul, Grummet, Jeremy, Mitterdorfer, Andrew J., Bishop, Conrad, Beardsley, Emma, Martin, Andrew, Lawrence, Nicola, Wong, Nicole, Chan, Howard, Pysarenko, Mariya, Harper, Matthew, Patel, Manish, Hamid, Akil, Davis, Ian and Hayne, Dickon (2015). RANDOMISED PHASE 3 TRIAL OF THE ADDITION OF MITOMYCIN TO BCG AS ADJUVANT INTRAVESICAL THERAPY FOR HIGH-RISK, NON-MUSCLE-INVASIVE BLADDER CANCER(ANZUP 1301). HOBOKEN: WILEY-BLACKWELL.
2015
Journal Article
Benefit of treatment of latent tuberculosis infection in individual patients
Dobler, Claudia C., Martin, Andrew and Marks, Guy B. (2015). Benefit of treatment of latent tuberculosis infection in individual patients. European Respiratory Journal, 46 (5), 1397-1406. doi: 10.1183/13993003.00577-2015
2015
Conference Publication
ANALYSING THE EVIDENCE - THE STATISTICS OF SMALL NUMBERS
Martin, Andrew (2015). ANALYSING THE EVIDENCE - THE STATISTICS OF SMALL NUMBERS. HOBOKEN: WILEY-BLACKWELL.
2015
Conference Publication
RANDOMISED PHASE 3 DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF METHOXYFLURANE WITH PERIPROSTATIC LOCAL ANAESTHESIA TO REDUCE THE DISCOMFORT OF TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY (PAIN-FREE TRUS B): ANZUP 1501
Grummet, Jeremy, Davis, Ian, Martin, Andrew, Buchan, Nicholas, Chalasani, Venu, Frydenberg, Mark, Hayne, Dickon, Lalak, Andre, Patel, Manish, Williams, Andrew, Woo, Henry, Lawrence, Nicola, Chan, Howard, Bishop, Claudia, Wong, Nicole, Coskinas, Xanthi and Stockler, Martin (2015). RANDOMISED PHASE 3 DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF METHOXYFLURANE WITH PERIPROSTATIC LOCAL ANAESTHESIA TO REDUCE THE DISCOMFORT OF TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY (PAIN-FREE TRUS B): ANZUP 1501. HOBOKEN: WILEY-BLACKWELL.
2015
Conference Publication
RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN ANDROGEN DEPRIVATION THERAPY WITH RADIATION THERAPY FOR HIGH RISK, CLINICALLY LOCALISED, PROSTATE CANCER: ENZARAD (ANZUP 1303)
Williams, Scott G., Davis, Ian D., Sweeney, Christopher, Stockler, Martin R., Martin, Andrew, Hague, Wendy, Coskinas, Xanthi, Long, Anne, Yip, Sonia, Tu, Emily, Chan, Howard, Lawrence, Nicky, McDermott, Ray, Hughes, Simon, Marchesin, Vittorio, Deignan, Olwyn and Nguyen, Paul L. (2015). RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN ANDROGEN DEPRIVATION THERAPY WITH RADIATION THERAPY FOR HIGH RISK, CLINICALLY LOCALISED, PROSTATE CANCER: ENZARAD (ANZUP 1303). HOBOKEN: WILEY-BLACKWELL.
2015
Conference Publication
RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN FIRST LINE ANDROGEN DEPRIVATION THERAPY FOR METASTATIC PROSTATE CANCER: THE ANZUP ENZAMET TRIAL (ANZUP 1304)
Davis, Ian, Stockler, Martin, Martin, Andrew, Hague, Wendy, Coskinas, Xanthi, Yip, Sonia, Dazo, Carlo, Long, Anne, Lawrence, Nicky, Chan, Howard, McDermott, Ray, Chowdhury, Simon, Marchesin, Vittorio, Deignan, Olwyn, Parulekar, Wendy, Suris, Alexander Montenegro and Sweeney, Christopher (2015). RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN FIRST LINE ANDROGEN DEPRIVATION THERAPY FOR METASTATIC PROSTATE CANCER: THE ANZUP ENZAMET TRIAL (ANZUP 1304). HOBOKEN: WILEY-BLACKWELL.
2015
Journal Article
A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention
Chen, Andrew C., Martin, Andrew J., Choy, Bonita, Fernandez-Penas, Pablo, Dalziell, Robyn A., McKenzie, Catriona A., Scolyer, Richard A., Dhillon, Haryana M., Vardy, Janette L., Kricker, Anne, George, Gayathri St., Chinniah, Niranthari, Halliday, Gary M. and Damian, Diona L. (2015). A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. New England Journal of Medicine, 373 (17), 1618-1626. doi: 10.1056/NEJMoa1506197
2015
Conference Publication
Discussing and prescribing expensive unfunded anticancer drugs in Australia
Karikios, D., Mileshkin, L., Martin, A., Ferraro, D. and Stockler, M. (2015). Discussing and prescribing expensive unfunded anticancer drugs in Australia. European Cancer Congress, Vienna Austria, 2015. OXFORD: ELSEVIER SCI LTD. doi: 10.1016/S0959-8049(16)30506-8
2015
Journal Article
Trans Tasman Radiation Oncology Group: development of the Assessment of New Radiation Oncology Technology and Treatments (ANROTAT) Framework
Duchesne, Gillian M., Grand, Mel, Kron, Tomas, Haworth, Annette, Corry, June, Jackson, Michael, Ng, Michael, Besuijen, Deidre, Carter, Hannah E., Martin, Andrew, Schofield, Deborah, Gebski, Val, Torony, Joan, Kovacev, Olga, Amin, Rowena and Burmeister, Bryan (2015). Trans Tasman Radiation Oncology Group: development of the Assessment of New Radiation Oncology Technology and Treatments (ANROTAT) Framework. Journal of Medical Imaging and Radiation Oncology, 59 (3), 363-370. doi: 10.1111/1754-9485.12255
2015
Journal Article
EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma
Davis, Ian D., Long, A., Yip, S., Espinoza, D., Thompson, J. F., Kichenadasse, G., Harrison, M., Lowenthal, R. M., Pavlakis, N., Azad, A., Kannourakis, G., Steer, C., Goldstein, D., Shapiro, J., Harvie, R., Jovanovic, L., Hudson, A. L., Nelson, C. C., Stockler, M. R. and Martin, A. (2015). EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. Annals of Oncology, 26 (6), 1118-1123. doi: 10.1093/annonc/mdv078
2015
Journal Article
Protocol for the CHEST Australia trial: A phase II randomised controlled trial of an intervention to reduce time-to-consult with symptoms of lung cancer
Murray, Sonya R., Murchie, Peter, Campbell, Neil, Walter, Fiona M., Mazza, Danielle, Habgood, Emily, Kutzer, Yvonne, Martin, Andrew, Goodall, Stephen, Barnes, David J. and Emery, Jon D (2015). Protocol for the CHEST Australia trial: A phase II randomised controlled trial of an intervention to reduce time-to-consult with symptoms of lung cancer. BMJ Open, 5 (5) e008046, 1-7. doi: 10.1136/bmjopen-2015-008046
2015
Conference Publication
A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: the P3BEP Trial (Anzup 1302)
Lawrence, Nicola, Toner, Guy, Martin, Andrew, Stockler, Martin, Yeung, Annie, Wong, Nicole, Thomson, Damien, Gebski, Val, Yip, Sonia, King, Madeleine, Friedlander, Michael, Quinn, David, Tan, Thean Hsiang, Chan, Howard, Hanning, Fritha, Weickhardt, Andrew, Jeffery, Mark, Stevanovic, Amanda, Hovey, Elizabeth, Wyld, David, Davis, Ian and Grimison, Peter (2015). A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: the P3BEP Trial (Anzup 1302). COSA’s 42nd Annual Scientific Meeting. Rare Cancers: Common Goals, Hobart, Australia, 17–19 November 2015. Chichester, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.12432_2
2014
Journal Article
Physical activity and fitness in women with metastatic breast cancer
Yee, Jasmine, Davis, Glen M., Beith, Jane M., Wilcken, Nicholas, Currow, David, Emery, Jon, Phillips, Jane, Martin, Andrew, Hui, Rina, Harrison, Michelle, Segelov, Eva and Kilbreath, Sharon L. (2014). Physical activity and fitness in women with metastatic breast cancer. Journal of Cancer Survivorship, 8 (4), 647-656. doi: 10.1007/s11764-014-0378-y
2014
Conference Publication
THE PROCARE TRIAL: A PHASE II RANDOMISED CONTROLLED TRIAL OF SHARED CARE FOR FOLLOW-UP OF MEN WITH PROSTATE CANCER
Emery, Jon, Schofield, Penny, Jefford, Michael, King, Madeleine, Pirotta, Marie, Hayne, Dickon, Martin, Andrew, Trevena, Lyndal, Lim, Tee and Constable, Roger (2014). THE PROCARE TRIAL: A PHASE II RANDOMISED CONTROLLED TRIAL OF SHARED CARE FOR FOLLOW-UP OF MEN WITH PROSTATE CANCER. HOBOKEN: WILEY-BLACKWELL.
2014
Journal Article
Do women notice the impact of childbirth-related levator trauma on pelvic floor and sexual function? Results of an observational ultrasound study
Thibault-Gagnon, Stéphanie, Yusuf, Sara, Langer, Suzanne, Wong, Vivien, Shek, Ka Lai, Martin, Andrew and Dietz, Hans Peter (2014). Do women notice the impact of childbirth-related levator trauma on pelvic floor and sexual function? Results of an observational ultrasound study. International Urogynecology Journal, 25 (10), 1389-1398. doi: 10.1007/s00192-014-2331-z
2014
Journal Article
A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed
Carter, Hannah E., Martin, Andrew, Schofield, Deborah, Duchesne, Gillian, Haworth, Annette, Hornby, Colin, Sidhom, Mark and Jackson, Michael (2014). A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed. Radiotherapy and Oncology, 112 (2), 187-193. doi: 10.1016/j.radonc.2014.03.020
2014
Journal Article
The relationships between obsessive-compulsive symptom dimensions and cognitions in obsessive-compulsive disorder
Brakoulias, Vlasios, Starcevic, Vladan, Berle, David, Milicevic, Denise, Hannan, Anthony and Martin, Andrew (2014). The relationships between obsessive-compulsive symptom dimensions and cognitions in obsessive-compulsive disorder. Psychiatric Quarterly, 85 (2), 133-142. doi: 10.1007/s11126-013-9278-y
2014
Conference Publication
The use of 3-dimensional ultrasound of the pelvic floor to predict recurrence risk after pelvic reconstructive surgery
Rodrigo, Natassia, Wong, Vivien, Shek, Ka Lai, Martin, Andrew and Dietz, Hans Peter (2014). The use of 3-dimensional ultrasound of the pelvic floor to predict recurrence risk after pelvic reconstructive surgery. Blackwell Publishing. doi: 10.1111/ajo.12171
Funding
Current funding
Supervision
Availability
- Professor Andrew Martin is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Advanced methods for biomarker informed endometrial cancer
Associate Advisor
Other advisors: Dr Eva Baxter, Dr Zoe West, Professor Andreas Obermair
Media
Enquiries
For media enquiries about Professor Andrew Martin's areas of expertise, story ideas and help finding experts, contact our Media team: